Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM. et al, (2024), JAMA, 331, 1460 - 1470
Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.
Yarmolinsky J. et al, (2024), EBioMedicine, 100
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J. et al, (2023), Diabetologia, 66, 1481 - 1500
Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.
Darst BF. et al, (2023), Am J Hum Genet, 110, 1200 - 1206
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Hamdy FC. et al, (2023), N Engl J Med, 388, 1547 - 1558
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Keeney E. et al, (2022), Pharmacoeconomics, 40, 1207 - 1220
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.
Buhigas C. et al, (2022), Mol Cancer, 21
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
Lane JA. et al, (2022), BJU Int, 130, 370 - 380
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.
Lloyd P. et al, (2022), World J Urol, 40, 119 - 126
Correction to 'Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation'.
Gaughan L. et al, (2021), Nucleic Acids Res, 49, 10203 - 10206
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.
Karlsson Q. et al, (2021), Eur Urol Oncol, 4, 570 - 579
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.
Karunamuni RA. et al, (2021), Prostate Cancer Prostatic Dis, 24, 532 - 541
Identification of a serum biomarker signature associated with metastatic prostate cancer.
Kuci Emruli V. et al, (2021), Proteomics Clin Appl, 15
KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.
Lin H-Y. et al, (2021), Sci Rep, 11
Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.
Sutton E. et al, (2021), Cancer Causes Control, 32, 261 - 269
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.
Huynh-Le M-P. et al, (2021), Nat Commun, 12
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.
Conti DV. et al, (2021), Nat Genet, 53, 65 - 75
The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.
Brandão A. et al, (2020), Cancers (Basel), 12